Is Eiko Lifescience overvalued or undervalued?

As of 18 July 2025, Eiko Lifescience has moved from a fair valuation to an expensive rating. The company is currently considered overvalued based on its high valuation metrics. Key ratios include a PE Ratio of 53.21, an EV to EBIT of 64.00, and an EV to EBITDA of 40.42.
In comparison to its peers, Eiko Lifescience's PE ratio significantly exceeds that of Life Insurance, which stands at 12.08, and Bajaj Finserv at 36.56, indicating a substantial premium for Eiko despite its lower return metrics, such as a ROCE of 2.31% and ROE of 2.63%. While Eiko has shown a positive return of 2.64% over the past week, its year-to-date performance of -8.38% contrasts sharply with the Sensex's 4.63% gain, reinforcing the notion that the stock may be overvalued in its current market position.